Spectranetics Corp.
Spectranetics closes $230M AngioScore buy
Colorado-based Spectranetics (NSDQ:SPNC) announced today that it consummated its $230 million acquisition of California-based AngioScore, adding that milestones payments are also on the forecast.
MGH researchers gain $30 million grant to build brain implants for treating mental illness | Medtech funding for the week of May 26, 2014
M&A: Spectranetics prepares $200M offering to fund $230M AngioScore bid
Medtech legal news for the week of Mar. 10, 2014
Ex-Spectranetics CEO’s conviction stands
Former Spectranetics (NSDQ:SPNC) CEO John Schulte’s 2012 conviction on a single count of lying to federal investigators survived his appeal to an appeals court, meaning his sentence of a year’s probation will stand.
Spectranetics takes Thermopeutix to court over distribution deal
Spectranetics (NSDQ:SPNC) and Thermopeutix are engaged in a full-on legal battle over the Tapas catheter, an infusion system the companies agreed sell using pooled resources in a distribution deal inked in late 2011.
Mela Sciences CEO resigns | Personnel Moves
Long-time Mela Sciences (NSDQ:MELA) CEO Joseph Gulfo resigned last week from his position as chief executive, president, chairman and member of the board. Gulfo had been Mela’s CEO since 2004, and company documents did not cite a reason for his resignation.
Medical device tax: How much are companies paying to government for healthcare reform?
In January 2013, Medical device companies began paying a 2.3% excise tax on U.S. Sales in order to pay for the Patient Protection and Affordable Care Act.
The levy is expected to generate some $30 billion over the next 10 years.
MassDevice.com is tracking the tally paid by several medical device companies, based on quarterly earnings report for the first quarter of 2013. We will update the list as more companies returns file in.
Tallies based on companies with Q1 earnings ended on March 31, 2013
Medical device tax helps push Spectranetics further into the red in Q1
Colorado-based medical device maker Spectranetics (NSDQ:SPNC) broke out the red ink in 2013, blaming the swing partly on the newly implemented medtech excise tax, which requires that companies pay a 2.3% levy on all U.S. sales of applicable medical devices.